Artelo Biosciences Files Provisional Patent Application For ART27.13 As Monotherapy And In Combination With GLP-1 Receptor Agonists
As reported, ART27.13 produced approximately 40% weight loss in combination with semaglutide and approximately 20% as monotherapy, comparable to semaglutide, in obese mice over four weeksApplication expands Artelo’s
Artelo filed paperwork to protect a new medicine called ART27.13. In early mouse tests, it helped with weight loss alone and better with a popular diabetes drug, which is why the company wants patent protection.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.